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Background: Short stature affects approximately 2% of children, representing one of the more frequent
disorders for which clinical attention is sought during childhood. Despite assumed genetic heterogeneity,
mutations or deletions of the short stature homeobox-containing gene (SHOX) are found quite frequently in
subjects with short stature. Haploinsufficiency of the SHOX gene causes short stature with highly variable
clinical severity, ranging from isolated short stature without dysmorphic features to Le´ri-Weill syndrome, and
with no functional copy of the SHOX gene, Langer syndrome.
Methods: To characterise the clinical and molecular spectrum of SHOX deficiency in childhood we assessed
the association between genotype and phenotype in a large cohort of children of short stature from 14
countries.
Results: Screening of 1608 unrelated individuals with sporadic or familial short stature revealed SHOX
mutations or deletions in 68 individuals (4.2%): complete deletions in 48 (70.6%), partial deletions in 4 (5.9%)
and point mutations in 16 individuals (23.5%). Although mean height standard deviation score (SDS) was not
different between participants of short stature with or without identified SHOX gene defects (–2.6 vs –2.6),
detailed examination revealed that certain bone deformities and dysmorphic signs, such as short forearm and
lower leg, cubitus valgus, Madelung deformity, high-arched palate and muscular hypertrophy, differed
markedly between participants with or without SHOX gene defects (p,0.001). Phenotypic data were also
compared for 33 children with Turner syndrome in whom haploinsufficiency of SHOX is thought to be
responsible for the height deficit.
Conclusion: A phenotype scoring system was developed that could assist in identifying the most
appropriate subjects for SHOX testing. This study offers a detailed genotype-phenotype analysis in a
large cohort of children of short stature, and provides quantitative clinical guidelines for testing of the SHOX
gene.
S
hort stature is a developmental, multifactorial condition
with a strong genetic component. Although several genes
have been reported to be associated with longitudinal
growth, they account only for a small proportion of cases of
short stature.1 2 One such gene is the short-stature homeobox-
containing gene (SHOX), which encodes a homeodomain
transcription factor3 and is believed to be responsible for the
height deficit associated with Turner syndrome.4–6 Mutations in
the SHOX gene are one of the more frequent genetic causes of
short stature in individuals with isolated or familial short
stature.7–11
Significant evidence points to an important role for SHOX
as a mediator of linear growth. First, the gene is expressed in
the developing skeleton during fetal life6 and is specifically
expressed in bone marrow fibroblasts and proliferating and
hypertrophic chondrocytes3–5 12 13; second, deficiency of SHOX
at the growth plate is associated with marked disorganisa-
tion of chondrocyte proliferation14; and third, there is a dose-
dependent association between the number of active copies
of the SHOX gene and height, such that SHOX haploinsuffi-
ciency is associated with short stature, whereas SHOX overdose
as seen in sex-chromosome polyploidy is associated with tall
stature.15
More than 50 different mutations in the SHOX gene
associated with short stature in subjects previously described
as ‘‘idiopathic’’ or in subjects with Le´ri-Weill syndrome (LWS)
or Langer syndrome have been reported and assembled in the
SHOX gene mutation database (www.shox.uni-hd.de).16 This
database has been established to provide clinicians and
scientists access to a central source of information about
SHOX mutations. Indeed, the phenotype can vary from extreme
dwarfism, mesomelia (short forearms and short lower legs) and
limb deformity as seen in Langer syndrome (two defective or
absent SHOX alleles) to disproportionate short stature and
mesomelia as seen in LWS and Turner syndrome (one absent
SHOX allele), to apparently isolated short stature with no other
obvious clinical signs, often referred to as ‘‘idiopathic’’ short
stature.5 17 18 The typical mesomelia and Madelung deformity
(clinical finding of dinner fork-like deformity of the wrist) of
LWS are more prevalent in females, but often do not become
apparent before puberty.10 19 20 The clinical phenotype repre-
sents a continuum from very severe, disproportionate short
stature to milder short stature with or without a number of
other clinical and radiological abnormalities, making the
distinction between LWS and non-LWS rather arbitrary. Even
within a single family with an identical genetic defect in all
affected members, the phenotype can vary considerably.21 This
phenotypic variability is seen in many other genetic disorders,
such that the classic boundaries between syndromic and
non-syndromic forms are blurred, although identical mutations
Abbreviations: BMI, body mass index; ISS, idiopathic short stature; LWS,
Leri-Weill syndrome; PCR, polymerase chain reaction; SDS, standard
deviation score; SHOX, short-stature homeobox containing gene
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are present.22 Thus, there is no reliable basis for strictly
distinguishing syndromic and non-syndromic phenotypes
caused by the same mutation genotypes.
The aim of this study was to determine the phenotypical and
molecular spectrum of SHOX deficiency in a large group of
children with short stature and to develop a scoring system to
aid in future selection of the most appropriate patients for
diagnostic SHOX testing.
PARTICIPANTS AND METHODS
The study was conducted in accordance with the principles of
the Declaration of Helsinki/Good Clinical Practice and was
approved by the ethics committees of the participating
institutions. Investigators obtained written, informed consent
from the participants’ parent(s) or legal guardian(s) before
conducting study-related procedures.
Participants
We studied 1608 pre-pubertal children with short stature from
14 countries: Belgium (n = 96), Canada (n = 96), Croatia
(n = 74), Czech Republic (n = 171), France (n = 138),
Germany (n = 200), Hungary (n = 55), India (n = 216),
Netherlands (n = 6), Poland (n = 93), Russia (n = 23), Spain
(n = 181), Turkey (n = 114), USA (n = 145). The participants’
ethnic origins were: Caucasian 1348 (83.8%), Western Asian
227 (14.1%), Eastern Asian 9 (0.6%), Hispanic 10 (0.6%),
African–American 7 (0.4%) and others 7 (0.4%). Subjects were
invited to participate in genetic screening for this study if they
fulfilled the following entry criteria: chronological age >3 years
and pre-pubertal (males: genital stage Tanner 1 and testes
(2 ml; females: breast stage Tanner 1); height ,3rd percentile
of the local reference range or height ,10th percentile with
height velocity ,25th percentile; bone age ,10 years for boys
and ,8 years for girls or ,9 years for patients with Turner
syndrome; no GH deficiency or GH resistance; no chronic
disease; and no known growth-influencing medications.
Study participants were screened for deletions or mutations
in the SHOX gene to determine their eligibility for participation
in a growth hormone intervention study23. This cohort of
participants with short stature does not overlap with partici-
pants from a previous study that investigated the prevalence of
SHOX deficiency in children with idiopathic short stature
(ISS)7. For comparison, a group of participants with Turner
syndrome (n = 33) was included. The ethnic backgrounds of
these participants were: 24 Caucasian (72.7%), 7 Western Asian
(21.2%) and 2 Eastern Asian (6.1%).
Clinical assessments
Height was measured with calibrated stadiometers, and a
number of anthropometric measures were assessed using
standardised procedures and equipment to quantify possible
disproportion: sitting height, arm span, forearm and upper arm
length, lower leg length and the circumferences of forearm,
upper arm, lower leg and upper leg.24 25 Investigators were
trained on these anthropometric techniques at study initiation.
In addition, investigators were requested to report the presence
or absence of a number of defined dysmorphic signs often
observed in patients with LWS that were listed on the case
report forms.
DNA analyses
DNA preparation and PCR
Genomic DNA was prepared from 0.5 ml peripheral blood using
the PUREGENE DNA Isolation kit (Gentra Systems,
Minneapolis, MN, USA). PCR were performed as previously
described by Rappold et al, 2002.7
PCR-based microsatel l i te analysis
To look for evidence of a SHOX gene deletion, two micro-
satellites in the vicinity of the SHOX locus (CA-SHOX, CAII)
were PCR-amplified and analysed on polyacrylamide gels for
homo- or heterozygosity for the size of the microsatellite.
Genomic DNA (100 ng) was amplified with 20 pmol of each of
the primers DXYS201 (SHOX 5CA forward/reverse: CAT GTC
ATA TAT ATA TGT GAT CC/GAC ACA GAA ATC CTT CAT AAA).
PCR was performed using 2 U of Goldstar DNA Polymerase
(Eurogentec, Cologne, Germany) in the buffer provided with
the enzyme, 10 pmol/dNTP (MBI) and 75 mmol/MgCl2 in a
Peltier Thermal Cycler (MJ-Research) (PTC-200) starting with
denaturation (95 C˚ (5 min)) followed by 35 cycles of amplifica-
tion (95 C˚ (30 s), 55 C˚ (30 s) and 72 C˚ (45 s)) and a final
elongation step (72 C˚ (5 min)). The PCR products were
separated on polyacrylamide gels (10%) and analysed after
silver staining.
FISH analysis
Biotinylated cosmid DNA was hybridised to metaphase
chromosomes from stimulated lymphocytes of 247 participants
under conditions previously described.26 FISH was performed
using the SHOX-containing cosmid 34F5 (LLN0YCO39M934F5)5.
Mutation analysis
Mutation screening was performed by denaturing high
performance liquid chromatography (DHPLC), using a WAVE
DNA-Fragment Analysis System (Transgenomic Inc., Cheshire,
UK). Mutation detection relies on differential binding to the
column of homo- and heteroduplexes, which are generated by
denaturing PCR products at 95 C˚ for five minutes and cooling
them slowly (–2 C˚ per cycle, 44 cycles) to allow renaturing.
Analysis was confined to the coding regions of the SHOX gene
(exons 2–6). Primer sequences and PCR conditions were: exon
2 forward/reverse: CGC GGG GAG ACG CGC GCA TCC/GGC
GCC GAA CCC CAG GAG GAG GGC; 63 C˚/65 C˚/66 C˚; exon 3
forward/reverse: GCC ACG TTG CGC AAA ACC TC/CCC GAG
GAC CAG GCG ATG; 64 C˚/65 C˚/67 C˚; exons 4 and 5 were
amplified together: exon 4 forward: GGG AGG CTG GGC TGG
GTT C; 62 C˚/64 C˚/65 C˚; exon 5 reverse: GGA AGG GAG CAG
CAG GTC C; 62 C˚/64 C˚/65 C˚; exon 6a forward/reverse: GTC CCC
ATC CTG CGC CCT CAC CC/GCG CGG AGC CCG GGA GTC CG;
66 C˚/68 C˚/67 C˚).
Sequencing
Sequencing was performed on a MegaBACE sequencer
(Amersham Bioscience, Piscataway, NJ, USA) using the
DYEnamic ET terminator Cycle Sequencing Kit (CGE
Healthcare, Freiburg, Germany) following the manufacturer’s
protocol . Sequencing reactions were performed on both DNA
strands. Sequences were analysed using the Clustal program
(German Cancer Research Center, Biocomputing Facility
HUSAR, Heidelberg, Germany).
Single nucleotide polymorphism (SNP)-based
screening
Although the majority of DNA samples were analysed accord-
ing to the methods described above, 275 participants had DNA
analyses for SHOX deletions and mutations performed using a
commercially available assay (SHOXDNAdx, Esoterix Inc,
Calabasas Hills, CA, USA).27
Statistical analyses
Because the majority of participants originated from European
countries, standard deviation scores (SDS) for height and the
various anthropometric parameters were calculated using
central European references.24 The exception was lower leg
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length, for which the reference range of Ross et al25 was used.
Values were adjusted for the actual chronological age by linear
interpolation. Body–mass index (BMI, kg/m2) was converted to
SDS using the method of Cole.28 Comparisons between groups
were performed using one-way analysis of variance (ANOVA)
for continuous variables and Fisher exact tests for categorical
variables at a two-sided significance level of 0.05.
For the development of a quantitative scoring system to assist
in identifying patients for SHOX gene testing, logistic regression
models were developed with confirmed SHOX deficiency (yes/
no) as the dependent variable and various explanatory
variables, including clinical diagnosis of LWS in the participant
or relative(s), dysmorphic signs and anthropometric measures.
The continuous variables were converted to categorical vari-
ables by applying defined cut-offs. For each group (SHOX and
non-SHOX) the median for the particular variable was
determined, and the mean of the two medians was then
calculated and used as the cut-off. Variables were first tested
one at a time, and included in the models only if there was a
significant mean difference between the SHOX deficient and
non-SHOX deficient groups. Next, the stepwise selection
procedure was used to develop the models and the models
were tested for lack of fit by applying the Hosmer–Lemeshow
statistic. Scoring systems were developed, which included only
those variables that contributed significantly to the logistic
models as score items. The odds ratios generated by the logistic
models were then rounded to the nearest integer and used as
the score weights. Various score systems were applied to the
study population and sensitivity, specificity, accuracy, and
positive predictive values were calculated for different score
point cut-offs.
RESULTS
A large cohort of 1608 children with short stature was screened
for deletions and intragenic mutations of the SHOX gene. The
physician-designated clinical diagnosis (LWS vs ISS) was
collected at the entry of the study. Fifty-five participants
(3.4%) were diagnosed with LWS; of the remaining 1553
participants 1534 were diagnosed as having ISS and for the
other 19 participants there was no diagnosis or diagnoses other
than LWS or ISS. SHOX defects were identified in 68 of the 1608
screened participants (4.2%), with 32/55 (58%) diagnosed with
LWS and 34/1534 (2.2%) diagnosed with ISS, while two
participants were not classified. The analysis for SHOX defects
followed a step-wise process. To screen for a possible gene
deletion, the first analysis determined the presence or absence
of heterozygosity for a CA-repeat marker 14 kb (DXYS201) and
CAII 34 kb upstream of the SHOX gene. When only a single
allele size of these two markers was detected, implying homo-
or hemizygosity, the next step was a FISH analysis using the
SHOX-containing cosmid LLN0YCO39M934F5 to verify a puta-
tive deletion. Forty-eight participants (70.6%) had complete
SHOX deletions and 4/68 (5.9%) had partial (small intragenic)
deletions as indicated by a reduced FISH signal on one of the
sex chromosomes. Intragenic mutations were detected in exons
2–6 of the coding sequence in 16/68 (23.5%) participants: 10
participants had missense mutations, 5 had nonsense muta-
tions and 1 had a small duplication (table 1). Seven of the 16
mutations have not been reported previously. In vitro func-
tional analyses of four missense mutations demonstrated
reduced DNA binding (R168W), reduced dimerisation
(L132V) or impaired nuclear translocation (A170P, R173H).29 30
Demographic and baseline clinical characteristics of the
children with or without SHOX gene defects are shown in
table 2. Although more males than females were enrolled in
this study (952 (60%) male vs 656 (40%) female), the sex
distribution of confirmed SHOX defects was reversed, with 54%
of molecular defects being in females and 46% in males. As
expected, children with SHOX deficiency had a significantly
higher percentage of first-degree relatives with LWS or Langer
syndrome than those without SHOX deficiency: fathers: 9.7% vs
0.5% (p,0.001), mothers: 26.6% vs 1.6% (p,0.001), siblings:
26.0% vs 2.0% (p,0.001). This finding is reflected by the
decreased target height, which supports the concept of
pseudoautosomal dominant inheritance of SHOX deficiency.
SHOX testing was also performed in either one (n = 8) or both
(n = 17) parents of 25 participants with SHOX deficiency. In 14
of 17 (82%) families in which both parents were tested, either
the father or the mother had a SHOX defect; in no family did
both parents have a SHOX defect. A SHOX mutation was found
in 10 of 18 tested fathers (56%) and 8 of 24 tested mothers
(33%). In all 25 cases in which DNA was also available for
Table 1 Point mutations in the SHOX gene
Exon
Amino acid
change Nucleotide change Mutation type Diagnosis New mutation/previously reported
2 E61X c.181G.T Nonsense LWS New
3 Q112P c.335A.C Missense ISS New
3 K116E c.346A.G Missense ISS New
3 L132V c.394C.G Missense LWS Grigelioniene et al 200039
Schneider et al 200529
3 Y141D c.421T.G Missense ISS Schneider et al 200529
3 E148X c.442G.T Nonsense LWS New
4 W164X c.492G.A Nonsense ISS New
4 R168W c.502C.T Missense ISS Schneider et al 200529
4 R168L c.503G.T Missense ISS New
4 A170P c.508G.C Missense ISS Schneider et al 200529
Sabherwal et al 200430
4 R173H c.518G.A Missense LWS Schneider et al 200529
Binder et al 200310
5 R195X c.583C.T Nonsense LWS Rao et al 19975
Ross et al 200538
5 R195X c.583C.T Nonsense LWS Rao et al 19975
Ross et al 200538
6a insH229-L232 c.685-696insCAC
CCGCACCTG
Duplication ISS New
6b X226R c.676T.C Missense ISS Ross et al 200538
6b X226R c.676T.C Missense LWS Ross et al 200538
ISS, non-syndromic short stature; LWS, Le´ri-Weill syndrome.
The amino acid changes in bold indicate the homeobox.
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family members the mutations co-segregated with the pheno-
type of LWS or short stature.
Investigators were instructed to examine the participants at
screening for the presence of a specified list of dysmorphic signs
(table 3). A significant number of participants with a pre-study
diagnosis of ISS who were subsequently confirmed to have a
SHOX defect had some dysmorphic signs typical of LWS. Only a
few signs such as micrognathia, high-arched palate, short
forearm and Madelung deformity were significantly more
frequent in participants with a baseline clinical diagnosis of
LWS (table 3). For children with a clinical diagnosis of LWS
there was no statistically significant difference in the frequency
of dysmorphic signs between children who were subsequently
confirmed to have a SHOX defect (n = 32) and those without an
intragenic mutation of the SHOX gene (n = 23; data not
shown). For participants with a clinical diagnosis of non-
syndromic short stature (‘‘ISS’’) a number of clinical signs were
more prevalent in those with a molecularly confirmed SHOX
defect (n = 34) than in those without a SHOX defect (n = 1500;
table 4). Therefore, these physical signs (shortening or bowing
of the forearm, dislocation of the ulna at the elbow, bowing of
the tibia and appearance of muscular hypertrophy) appear to
represent clinical indicators for SHOX deficiency in short
children. In addition, participants with proven SHOX defects
had significantly greater mean body–mass index (BMI)
standard deviation score (SDS) than those without.
Because SHOX haploinsufficiency is also believed to underlie
the short stature and skeletal anomalies of Turner syndrome,
frequencies of dysmorphic signs were compared between
participants with Turner syndrome (n = 33) and those with
(n = 68) or without (n = 1540) confirmed SHOX deficiency
(table 5). While the majority of dysmorphic signs were not
different in frequency between the SHOX-deficient and Turner
syndrome groups, there were a few notable exceptions. High-
arched palate and cubitus valgus were substantially more
common in Turner syndrome, whereas short forearm or short
lower leg, Madelung deformity and muscular hypertrophy were
markedly more prevalent in the SHOX-deficient group.
To obtain an objective assessment of body proportions a
number of anthropometric measurements were performed.
Values were adjusted for standing height by calculating the
ratio (%) of the anthropometric measure divided by height
(table 6). Participants with SHOX deficiency had a significantly
greater sitting height and forearm, upper arm and upper leg
circumference adjusted for standing height. In contrast, height-
adjusted arm span, forearm length and lower leg length were
significantly shorter in participants with SHOX deficiency
compared with those without. These findings underline the
differences in frequency of dysmorphic signs between the
groups with and without SHOX deficiency and suggest
mesomelic disproportion and appearance of muscular hyper-
trophy as the most indicative features of SHOX deficiency.
There were no significant differences in dysmorphic signs or
anthropometric measures between participants with a missense
mutation within (n = 6) or outside (n = 5) the homeobox (data
not shown).
Although the above analyses elucidate the spectrum of
phenotypic findings in children with various forms of SHOX
deficiency, the variability of the phenotype makes it difficult to
decide whether or not SHOX testing is warranted for an
individual child. Therefore, to provide evidence-based scoring
systems for identifying the most appropriate children for SHOX
gene testing on clinical grounds, various logistic regression
models were developed with SHOX deficiency (yes/no) as the
dependent variable. Combinations of variables, including
diagnosis (LWS in subject or relatives), dysmorphic signs and
anthropometric variables that were significantly different
between participants with or without SHOX deficiency, were
included in the models as explanatory variables, and odds ratios
were calculated. The diagnosis of LWS or the presence of
Madelung deformity in the subject or in a family member
resulted in very high odds ratios in the models. Therefore,
to focus on the clinically more challenging subjects with
Table 2 Demographic and baseline data of patients with (SHOX) and without (non-SHOX) a
deletion or mutation in the SHOX gene and patients with Turner syndrome
Variable Non-SHOX SHOX
Turner
syndrome
p Value Non-
SHOX vs SHOX
p Value Turner
syndrome vs
SHOX
N 1540 68 33
Males/females (%) 60/40 46/54 0/100 0.023
LWS (%) 1.5 48.5 ,0.001
Age (years) 7.7 (2.4) 7.4 (2.5) 7.2 (2.0) 0.311 0.767
Height SDS –3.4 (1.0) –3.4 (1.1) –3.8 (0.8) 0.997 0.104
BMI SDS –0.6 (1.4) +0.4(1.1) –0.3 (1.2) ,0.001 0.023
TH SDS –1.3 (1.0) –1.5 (1.3) –0.6 (1.3) 0.205 ,0.001
Height SDS – TH SDS –2.1 (1.2) –1.9 (1.1) –3.1 (1.0) 0.156 ,0.001
BMI, body–mass index; LWS, Le´ri-Weill syndrome; SDS, standard deviation score; SHOX, short-stature homeobox
containing gene; TH, target height.
Continuous variables are shown as mean standard deviation (SD). p Values of categorical variables were calculated by
Fisher’s exact test and of continuous variables by one-way analysis of variance (ANOVA) (two-sided p values).
Table 3 Dysmorphic signs in patients with confirmed
SHOX deficiency
Dysmorphic sign
ISS
n = 34 (%)
LWS
n = 32 (%) p Values
Micrognathia 3 (8.8) 13 (40.6) 0.004
High-arched palate 9 (26.5) 25 (78.1) ,0.001
Short forearm 7 (20.6) 17 (53.1) 0.010
Bowing of forearm 4 (11.8) 11 (34.4) 0.040
Cubitus valgus 5 (14.7) 11 (34.4) 0.086
Short hands 7 (20.6) 5 (15.6) 0.752
Madelung deformity with pain 0 2 (6.3) 0.231
Madelung deformity without pain 2 (5.9) 12 (37.5) 0.002
Dislocation of ulna at elbow 3 (8.8) 1 (3.1) 0.614
Short lower leg 5 (14.7) 12 (37.5) 0.049
Bowing of tibia 5 (14.7) 10 (31.3) 0.145
Genu valgum 2 (5.9) 6 (18.8) 0.143
Short feet 6 (17.6) 4 (12.5) 0.734
Scoliosis 2 (5.9) 1 (3.1) 0.999
Muscular hypertrophy 9 (26.5) 14 (43.8) 0.197
Other dysmorphic signs 5 (14.7) 2 (6.3) 0.428
SHOX, short-stature homeobox containing gene.
Comparison between patients with non-syndromic short stature (ISS) and
patients with Le´ri-Weill syndrome (LWS). Note: the assignment to ISS or
LWS was not obtained in 2 patients.
p Values were calculated using Fisher’s exact test.
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non-syndromic short stature (‘‘ISS’’), these strong indicators of
SHOX deficiency were excluded from the models. The scoring
system presented in table 7 is based on the final logistic
regression model, using rounded odds ratios as weighted score
points. There was no evidence of lack of fit of the underlying
logistic model (lack of fit P = 0.81). The suggested scoring
system includes three anthropometric variables (arm span/
height, sitting height/height and body mass index (BMI)) and
five dysmorphic signs. This scoring system, in which a
maximum of 24 score points can be attained, was applied to
the study population to evaluate the performance of the score.
The dependence on various score point cutoffs of sensitivity,
specificity, accuracy and positive predictive value is shown in
Figure 1. At a cut-off of .4 points, sensitivity was 71% and the
positive predictive value was 11%; at .7 points the sensitivity
dropped to 61% while the positive predictive value increased to
19%.
DISCUSSION
This multi-centre, multi-national study was performed to
define a comprehensive clinical and molecular spectrum for
SHOX haploinsufficiency. Whereas the involvement of the SHOX
gene in short stature is well established, there is little
prospective quantitative data addressing the more subtle
clinical features and genotype-phenotype relationships in
participants with SHOX deficiency. We therefore evaluated the
growth and skeletal features of a large cohort of children with
short stature and performed a detailed analysis of their
anthropometric measures and dysmorphic features, comparing
the findings in participants with proven SHOX defects to those
in participants without demonstrable molecular SHOX defects.
We also compared the clinical features in children with isolated
SHOX deficiency to those seen in another model of SHOX
haploinsufficiency children with Turner syndrome; within the
cohort with isolated SHOX deficiency (ie, excluding partici-
pants with Turner syndrome), we compared the findings of
participants with the classical LWS phenotype with those
participants with more subtle phenotype, diagnosed before
entry to the study as ISS. Finally, we defined diagnostic criteria
that will allow clinicians to identify patients most likely to have
a SHOX gene abnormality and to target SHOX testing to these
patients.
SHOX mutations were identified in 4.2% of 1608 children
studied. However, this cohort was enriched for participants
with LWS, in whom the frequency of SHOX defects is
particularly high; when these participants were excluded and
only the participants with non-syndromic (or idiopathic) short
stature were included, the frequency of SHOX deficiency was
2.2%. This frequency is similar to the rates reported in previous
smaller studies in independent samples of children with ISS
using similar genetic and molecular methodologies7 10; how-
ever, it is lower than frequencies reported in other studies.8 9 11
These variable rates of detection of SHOX defects may in part
relate to methodological differences or to the different
population studied.11 31 32 We also did not screen for putative
enhancer mutations (‘‘downstream deletions’’) nor single exon
deletions. It is therefore likely that intragenic mutations due to
splice defects in the introns, regulatory mutations or single
exon deletions have been missed.
Short stature is a more frequent reason for referral to a
pediatric endocrine clinic for boys than for girls. Therefore, it
was not surprising that 60% of our study participants were
Table 5 Dysmorphic signs in patients without SHOX deficiency (non-SHOX), with SHOX deficiency (SHOX) and with Turner
syndrome; both the non-SHOX and SHOX groups include patients with Le´ri-Weill syndrome
Dysmorphic sign
Non-SHOX
n = 1540 (%)
SHOX
n = 68 (%)
Turner syndrome
n = 33 (%)
p Value Non-
SHOX vs SHOX
p Value SHOX vs
Turner syndrome
p Value Non-SHOX vs
Turner syndrome
Micrognathia 221 (14.4) 16 (23.5) 3 (9.1) 0.052 0.106 0.613
High-arched palate 457 (29.7) 34 (50.0) 24 (72.7) ,0.001 0.034 ,0.001
Short forearm 108 (7.0) 25 (36.8) 2 (6.1) ,0.001 ,0.001 0.999
Bowing of forearm 61 (4.0) 15 (22.1) 3 (9.1) ,0.001 0.165 0.148
Cubitus valgus 129 (8.4) 16 (23.5) 20 (60.6) ,0.001 ,0.001 ,0.001
Short hands 304 (19.7) 13 (19.1) 7 (21.2) 0.999 0.796 0.826
Madelung deformity with pain 5 (0.3) 2 (2.9) 0 0.032 0.999 0.999
Madelung deformity without pain 30 (1.9) 14 (20.6) 1 (3.0) ,0.001 0.019 0.485
Dislocation of ulna at elbow 8 (0.5) 5 (7.4) 0 ,0.001 0.170 0.999
Short lower leg 100 (6.5) 17 (25.0) 2 (6.1) ,0.001 0.029 0.999
Bowing of tibia 50 (3.2) 15 (22.1) 2 (6.1) ,0.001 0.050 0.298
Genu valgum 69 (4.5) 8 (11.8) 3 (9.1) 0.014 0.999 0.189
Short feet 198 (12.9) 11 (16.2) 2 (6.1) 0.459 0.212 0.423
Scoliosis 43 (2.8) 3 (4.4) 3 (9.1) 0.441 0.389 0.069
Muscular hypertrophy 142 (9.2) 24 (35.3) 1(3.0) ,0.001 ,0.001 0.357
Other dysmorphic signs 251 (16.3) 8 (11.8) 19 (57.6) 0.400 ,0.001 ,0.001
SHOX, short-stature homeobox containing gene.
p Values were calculated using Fisher’s exact test.
Table 4 Dysmorphic signs in patients with non-syndromic
short stature (ISS) excluding patients with Le´ri-Weill
syndrome, with unknown diagnosis or with a diagnosis
other than ISS
Dysmorphic sign
Non-SHOX
n = 1500 (%)
SHOX
n = 34 (%) p Value
Micrognathia 208 (13.9) 3 (8.8) 0.613
High-arched palate 438 (29.2) 9 (26.5) 0.850
Short forearm 97 (6.5) 7 (20.6) 0.006
Bowing of forearm 49 (3.3) 4 (11.8) 0.027
Cubitus valgus 116 (7.7) 5 (14.7) 0.183
Short hands 287 (19.1) 7 (20.6) 0.836
Madelung deformity with pain 4 (0.3) 0 0.999
Madelung deformity without pain 22 (1.5) 2 (5.9) 0.097
Dislocation of ulna at elbow 6 (0.4) 3 (8.8) ,0.001
Short lower leg 90 (6.0) 5 (14.7) 0.055
Bowing of tibia 39 (2.6) 5 (14.7) 0.002
Genu valgum 64 (4.3) 2 (5.9) 0.655
Short feet 187 (12.5) 6 (17.6) 0.427
Scoliosis 40 (2.7) 2 (5.9) 0.238
Muscular hypertrophy 132 (8.8) 9 (26.5) 0.003
Other dysmorphic signs 235 (15.7) 5 (14.7) 0.999
SHOX, short-stature homeobox containing gene.
Comparison between patients without confirmed SHOX deficiency (non-
SHOX) versus patients with confirmed SHOX deficiency (SHOX).
p Values were calculated using Fisher’s exact test.
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boys. However, it is interesting to note that SHOX gene defects
were confirmed in a greater proportion of tested girls than boys
(54% vs 46%). This finding is consistent with the greater
reported prevalence of LWS in females,33 hypothesised to result
from an effect of estrogen at the SHOX-deficient growth plate.20
If true, this effect may have led to an ascertainment bias toward
females with clinically significant skeletal anomalies.
Consistent with previous reports, the majority (52/68; 77%)
of mutations detected were complete or partial gene dele-
tions.7 10 11 21 The relatively high frequency of deletions has been
attributed to the structural composition of the pseudoautoso-
mal region, which may promote recombination, thereby
predisposing to deletion events.34 35 Notably, the majority of
deletions have been transmitted through the paternal allele
suggesting that the high recombination rate during male
meiosis is accountable for this phenomenon.36
Although the majority of the SHOX gene defects in this study
were large scale deletions, there were nevertheless a number of
novel intragenic mutations that may elucidate some aspects of
SHOX structure or function. The spectrum of intragenic
mutations in the SHOX gene in this and other studies is highly
heterogeneous. Including the seven novel mutations reported
here, more than 60 different mutations have been identified,
distributed throughout the coding regions of the gene (http://
www.shox.uni-hd.de). The majority of intragenic mutations are
missense mutations, and all missense mutations detected in
this study affect amino acids conserved between human,
chicken and fish, highlighting the functional importance of
these affected residues. None of these missense mutations was
detected in unaffected parents tested in this study or in 100
unaffected control individuals screened outside this study.
While the fact that the missense mutations segregate with the
phenotype provides evidence of the functional role of the
mutations, definitive proof requires in vitro demonstration of
disturbed activity of the encoded transcription factor.
Functional consequences have been demonstrated for the
mutants R168W, L132V, A170P and R173H with respect to
DNA binding, dimerisation or nuclear translocation of the
SHOX protein.29 30 However, the effect of Q112P, K116E,
insH229-L232 and X226R on SHOX activity is unknown.
Although it might have been expected that children with
molecular SHOX gene defects would have had more severe short
stature than those with normal SHOX genes, we found no
difference in the degree of short stature between those with or
without an identifiable SHOX gene defect; mean height was
–2.6 SDS in both groups. In fact, the most striking anthropo-
metric difference between SHOX-deficient and non-SHOX
deficient participants was the 1.0 SDS greater body mass index
(BMI) in the SHOX-deficient group (p,0.001). This finding is
interesting in light of the fact that participants with a working
diagnosis of ISS (who comprised half of the SHOX-deficient
group in our study) typically have BMI values in the low to low-
normal range, perhaps due to poor eating behaviour.37 However,
rather than reflecting obesity, the above average BMI for age
and sex in SHOX-deficient children likely reflects segmental
disproportion with rather normal trunk size but short legs.
Moreover, the relative increase in limb circumferences
Table 6 Anthropometric measures in patients with (SHOX) and without (non-SHOX) SHOX deficiency
Variable
Per cent of height (%)
p Value
Deviation from normal (cm)
Non-SHOX n = 1447 SHOX n = 65 Non-SHOX SHOX
Height SDS –3.3 (0.9) –3.4 (1.1) 0.673
Sitting height SDS –3.1 (1.1) –2.4 (1.4) ,0.001
Sitting height/Height 54.5 (3.0) 56.5 (3.0) ,0.001 +1.2 +3.9
Arm span/Height 97.5 (3.4) 95.2 (3.3) ,0.001 –2.8 –5.8
Forearm length/Height 14.9 (1.2) 14.3 (1.8) ,0.001 +0.4 –0.4
Upper arm length/Height 17.8 (1.5) 18.0 (1.8) 0.287 –0.5 –0.3
Lower leg length/Height 21.9 (1.7) 21.1 (2.3) ,0.001
Forearm circumference/Height 14.9 (1.4) 15.7 (1.6) ,0.001 +0.3 +1.3
Upper arm circumference/Height 15.5 (1.7) 16.6 (1.8) ,0.001 +0.1 +1.6
Lower leg circumference/Height 21.9 (1.7) 21.1 (2.3) ,0.001 +2.5 +1.5
Upper leg circumference/Height 29.5 (3.2) 31.8 (3.8) ,0.001 –3.1 –0.1
SHOX, short-stature homeobox containing gene.
Measures were related to standing height to evaluate disproportions; anthropometric measures as percentage of height were compared with the corresponding means of
normal 8 year-old children (Flu¨gel et al24) and were converted to differences in cm to give an impression of the magnitude of deviation.
Two-sided p values were calculated using analysis of variance (ANOVA); SDS (standard deviation score).
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Figure 1 Dependence of sensitivity, specificity, accuracy and positive
predictive value on cut-off score point; the vertical lines represent cut-offs of
.4 and .7 score points, respectively.
Table 7 Scoring system for identifying patients that qualify
for short-stature homeobox containing gene (SHOX) testing
based on clinical criteria
Score item Criterion Score points
Arm span/height ratio ,96.5% 2
Sitting height/height ratio .55.5% 2
Body–mass index .50th percentile 4
Cubitus valgus Yes 2
Short forearm Yes 3
Bowing of forearm Yes 3
Appearance of muscular hypertrophy Yes 3
Dislocation of ulna (at elbow) Yes 5
Total 24
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(discussed below) suggests increased muscle mass or muscular
hypertrophy, which may translate to a greater body mass
compared with the significantly reduced height of affected
individuals, leading in turn to an increase in BMI.
Apart from the increased BMI, the most reliable clinical
indicators of SHOX deficiency were disproportionate growth,
with shortening of the limbs compared with the trunk and
bowing of the forearm or lower leg. The limb shortening was
evidenced by reductions in the ratios of arm span and forearm
length to height and an increase in sitting height/height ratio in
the SHOX-deficient vs SHOX-sufficient group; furthermore,
arm span and forearm length vs height were all reduced in the
SHOX-deficient group compared with reference values for age.
These findings are consistent with other reports.10 38 All limb
circumferences (upper arm, forearm, upper leg and lower leg)
were relatively increased compared with height in SHOX
deficient vs non-SHOX deficient participants, and were
increased relative to reference values for all measures except
upper leg circumference/height. These findings of increased
limb circumferences were manifest clinically as the appearance
of muscular hypertrophy, which was significantly more
common in the SHOX-deficient participants, as previously
reported.21 Although it is possible that the apparent muscular
hypertrophy may result from unfavourable lever proportions of
the limbs, it may also represent a genuine developmental
phenomenon due to SHOX haploinsufficiency. Notably, these
findings were present in a significant number of participants
with the ‘‘ISS’’ phenotype as well as those with LWS, indicating
that these diagnoses represent a continuum, rather than
discrete entities.
The clinical features of SHOX deficiency beyond the effects
on long bone length, appear to represent changes in the
curvature or angularity of certain bones. As examples, the
following features were present in a significantly greater
proportion of participants with SHOX deficiency than those
without: forearm and tibial bowing, cubitus valgus and genu
valgum, Madelung deformity and ulnar dislocation at the
elbow. In addition, it should be mentioned that lower leg and
forearm x rays can be very helpful to detect deformities, which
are clinically not obvious. Furthermore, as reported previously,
a number of these features were also seen with increased
frequency in the Turner syndrome group, including high-
arched palate, forearm bowing, cubitus valgus, ulnar disloca-
tion, and a variety of other dysmorphic signs. Although the
phenotypic differences between SHOX-deficient participants
with LWS vs ‘‘ISS’’ were subtle, there were a number of
features that were significantly more common in children with
LWS than in those with the baseline clinical diagnosis of ISS,
including high-arched palate, Madelung deformity, micro-
gnathia and shortening and/or bowing of the forearm. These
alterations in the patterns of bone growth likely reflect the
disorganisation of the growth plate that has been reported in
association with SHOX deficiency.14 Despite some differences
between the diagnostic groups within this study in terms of
frequency of the various clinical findings, it has become clear
that there is no single phenotype of SHOX deficiency, but rather
that molecular defects of the SHOX gene may manifest a widely
varying spectrum of clinical severity, most likely reflecting other
generic influences on the expression of the genetic disorder.
The presence of LWS or Madelung deformity in an individual
participant or in a first degree relative in this study was an
overwhelming indicator for the presence of SHOX deficiency.
Therefore, all children with these clinical diagnoses should
undergo formal SHOX gene molecular analysis. However, the
same is not true for the milder forms of SHOX deficiency
detected in this study. In participants with non-syndromic
forms of short stature the key clinical features of SHOX
deficiency, evidenced by significant differences between the
SHOX-deficient and non-SHOX-deficient groups, were
increased BMI, short limbs relative to overall height (eg, short
forearm: 21% vs 7%; p = 0.006), evidence of muscular
hypertrophy (27% vs 9%; p = 0.003), and increased bowing or
angularity of various bones, particularly those of the lower leg
(tibial bowing: 15% vs 3%; p = 0.002) and forearm (12% vs 3%;
p = 0.027).
Although this study undertook a thorough assessment of the
phenotype of children with SHOX deficiency, we were unable to
determine any clear correlation between the specific SHOX gene
defect and the clinical features. For example, no consistent
differences could be discerned between participants with
complete SHOX gene deletions and those with missense
mutations resulting in conservative amino acid substitutions.
Furthermore, although SHOX haploinsufficiency is present in
both LWS and Turner syndrome and might be expected to
result in similar skeletal features, the findings of high-arched
palate and cubitus valgus were significantly more frequent in
children with Turner syndrome, whereas children with isolated
SHOX deficiency had a significantly greater frequency of
Madelung deformity, short forearm, short lower leg and
appearance of muscular hypertrophy. The basis for these
phenotypic differences is speculative: one suggested explana-
tion is that estrogen action at the growth plate in girls with
isolated SHOX deficiency (ie, normal gonadal function) may
exacerbate the effects of SHOX haploinsufficiency20; alterna-
tively, it may be hypothesised that haploinsufficiency of
additional X-chromosomal genes in girls with Turner syndrome
may mitigate the effects of SHOX deficiency to some degree. In
addition to the absence of a genotype-phenotype relationship
for SHOX gene defects, there also appear to be other defects that
manifest an indistinguishable clinical phenotype, evidenced by
the fact that a significant minority of participants with typical
dysmorphic signs of LWS had no detectable SHOX gene defect
in this and other studies.8 9 11 The absence of a clear molecular
basis for the LWS phenotype in a significant proportion of
participants suggests that a similar phenotype can be caused
either by intragenic mutations that may escape detection due to
their location in regulatory regions of the gene, or to defects at a
different, but perhaps related, genetic locus.
To provide a quantitative approach to determining the most
appropriate candidates for SHOX genetic testing, we integrated
the clinical and anthropometric findings reported here into a
pragmatic scoring system that optimises the selection of
patients who are less clinically obvious than those with LWS
and Madelung deformity. The score combines three anthropo-
metric variables (arm span/height ratio, sitting height/height
ratio and BMI), with five clinical variables (cubitus valgus,
short forearm, bowing of forearm, muscular hypertrophy and
dislocation of the ulna at the elbow), each of which represents
at least two points in the score system (table 7). The system was
then examined for sensitivity, specificity, positive predictive
value and accuracy using various total score values. On the
basis of these analyses, testing for SHOX deficiency is
recommended for participants with a score greater than four
or seven out of a total possible score of 24. The decision on
whether to choose the increased threshold score needs to take
into account the decrease in sensitivity, which means more
SHOX-deficient patients will be missed, versus the increase in
positive predictive value, which means more patients will be
tested positive for a SHOX defect.
In summary, SHOX defects represent a relatively frequent
cause of short stature, particularly in children with evidence—
which may sometimes be quite subtle—of shortening and/or
bowing of the forearms and lower legs. The presence of some of
the typical physical findings of LWS in children with the initial
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clinical diagnosis of ISS indicates that a very careful physical
examination, including measurement of body proportions,
must be performed before making the diagnosis of ISS. In
addition, x ray analysis of the lower leg and forearm can be very
important when distinguishing between ISS and LWS. The
presence of any combination of the following physical findings:
reduced arm span/height ratio, increased sitting height/height
ratio, above average BMI, Madelung deformity, cubitus valgus,
short or bowed forearm, dislocation of the ulna at the elbow, or
the appearance of muscular hypertrophy, should prompt the
clinician to obtain a molecular analysis of the SHOX gene.
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